# EDGAR Filing Document

**Accession Number:** 0000353278
**File Stem:** 0001171843-23-000946
**Filing Date:** 2023-2
**Character Count:** 6810
**Document Hash:** 4eef488a2ef5cba44627ea2b903e3401
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000946.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001171843-23-000946

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230214

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVO NORDISK A S
- **CENTRAL INDEX KEY:** 0000353278
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-82318
- **FILM NUMBER:** 23622629

**BUSINESS ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000
- **BUSINESS PHONE:** 4544448888

**MAIL ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO NORDISK A/S
- **DATE OF NAME CHANGE:** 19900807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO INDUSTRI A S /DENMARK/
- **DATE OF NAME CHANGE:** 19890811

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

***________________***

**FORM 6-K**

***________________***

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

February 14, 2023

***________________***

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé** 

**DK- 2880, Bagsvaerd** 

**Denmark**

(Address of principal executive offices)

***________________***

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X] Form 40-F [ ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [ ] No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

![](logo.jpg)

![](ca.jpg)

**Trading in Novo Nordisk shares by board members, executives and associated persons**

**Bagsværd, Denmark, 14 February 2023 —** This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

---

| | | |
|:---|:---|:---|
| **1** | **Details of the person discharging managerial responsibilities/person closely associated** | **Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board | Maziar Mike Doustdar |
|  | member/Executive/Associated Person |  |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> Internet:<br> www.novonordisk.com<br> CVR no:<br> 24 25 67 90 |
|  |  | Company announcement No 12/ 2023 | Company announcement No 12/ 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Description of the financial instrument, | Shares | Shares |
|  | type of instrument, |  |  |
|  | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale | Sale |
| c) | Price(s) and volume(s) |  |  |
|  |  | Price(s) | Volume(s) |
|  |  | DKK 990.58 | 25,625 shares |
| d) | Aggregated information |  |  |
|  | · Aggregated volume | 25,625 Shares | 25,625 Shares |
|  | · Price | DKK 990.58 | DKK 990.58 |
| e) | Date of the transaction | 2023-02-13 | 2023-02-13 |
| f) | Place of the transaction | Outside a trading venue |  |

---

 

*Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.*

**Contact for further information**

---

| | |
|:---|:---|
| **Media:** |  |
| **Ambre Brown Morley**<br> +45 3079 9289<br> abmo@novonordisk.com | **Natalia Salomao Abrahao (US)**<br> +1 848 304 1027<br> niaa@novonordisk.com |
| **Investors:** |  |
| **Daniel Muusmann Bohsen**<br> +45 3075 2175<br> dabo@novonordisk.com | **Jacob Martin Wiborg Rode**<br> +45 3075 5956<br> jrde@novonordisk.com |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> Internet:<br> www.novonordisk.com<br> CVR no:<br> 24 25 67 90 |
|  |  | Company announcement No 12/ 2023 | Company announcement No 12/ 2023 |

---

---

| | |
|:---|:---|
| **David Heiberg Landsted**<br> +45 3077 6915<br> dhel@novonordisk.com | **Mark Joseph Root (US)**<br> +1 848 213 3219<br> mjhr@novonordisk.com |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> Internet:<br> www.novonordisk.com<br> CVR no:<br> 24 25 67 90 |
|  |  | Company announcement No 12/ 2023 | Company announcement No 12/ 2023 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 14, 2023 NOVO NORDISK A/S <u>Lars Fruergaard Jørgensen</u> Chief Executive Officer